Two pharmaceutical companies seeking to swap a Federal Trade Commission case over paying to delay the release of generic drugs with an administrative remedy were disappointed by a federal judge Tuesday.

In a declaratory judgment lawsuit filed against the FTC by Watson Laboratories and Allergan Finance, U.S. District Judge Paul S. Diamond of the Eastern District of Pennsylvania dismissed the plaintiffs’ claims, noting that they had largely repeated their arguments used in a previous motion to dismiss the enforcement action.